ClinicalTrialsFinder

HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy Clinical Trials in Shanghai, Shanghai Municipality

1 recruitingShanghai, Shanghai Municipality, China

Showing 1–1 of 1 trials

Recruiting
Phase 3

A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy

HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
Jiangsu HengRui Medicine Co., Ltd.1,600 enrolled2 locationsNCT06126640